Sold as Theelin. Every FDA application for this active ingredient: 1 branded and 4 generic.
As of Nov 13, 2026, FDA lists 5 applications for Estrone (sold as Theelin), first approved Jun 12, 1941, with 0 new uses approved and 0 published complete response letters.
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jun 12, 1941 | TheelinNDA 3977 | Parkedale | 9 | Discontinued |
| Feb 21, 1979 | EstroneANDA 85239 | Dr Reddys | 16 | Discontinued |
| — | EstroneANDA 83397 | Watson Labs | 0 | Discontinued |
| — | Estrogenic SubstanceANDA 83488 | Wyeth Ayerst | 0 | Discontinued |
| — | Natural Estrogenic Substance-EstroneANDA 85237 | Watson Labs | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA
